Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Jan 06, 2018 1:26am
105 Views
Post# 27295982

RE:RE:RE:RE:Who is this guy?

RE:RE:RE:RE:Who is this guy?
smartmichel wrote:
longterm56 wrote: C'mon Smartmichel ... I'm interested in hearing your justifications for your conclusions based on *zero* input data ... where's *your* logic!!?!?!?!

 - LT


Hi Long term, I appreciate your consideration about my last post. This said, I only want to tell  on a 'ceteris paribus' basis, when you are waiting a bus at a stop, if you to leave because the car doesn't arrive since 30 minutes, at each next minute for lost time of waiting, you add chance (probabilities) to see the bus arrive. Leave the abribus and walk is statistically a bad decision.

I give you an example: 6 monhs ago at $8.72 SP, TH  with Ibalizumab was at a rumor/disclosure of a selling price  'to premium pricing in front of Egrifta' i.e. Around $60,000.  At last CC, CEO gave a hint of double gross price than that. The risk, on this element,  is now  50% better. Add the risk for the six others elements I submited yesterday and you have a rational about decision to buy or sale.
Submit With respect.


Maybe he didnt hold 6 months ago, maybe he bought the delay dip and is cashing in profits now.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities